Holen Sie sich die Stockscreener-App
37.49
2.68%
0.98
Handel nachbörslich:
37.49
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - simplywall.st
Income Plays: Can Crinetics Pharmaceuticals Inc stock outperform in a bear market2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces - Traders Union
(CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
WINTON GROUP Ltd Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Levels Update: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsMarket Activity Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. - Yahoo Finance
Should value investors consider Crinetics Pharmaceuticals Inc2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Will Crinetics Pharmaceuticals Inc. stock attract more institutional investorsInsider Buying & High Win Rate Trade Alerts - Naître et grandir
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Insider Trends: What is the dividend yield of Crinetics Pharmaceuticals IncJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
American Century Companies Inc. Has $47.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharma CFO Schilke sells $266k in stock By Investing.com - Investing.com Canada
Crinetics Pharma CFO Schilke sells $266k in stock - Investing.com
Insider Sell: Stephanie Okey Sells 3,000 Shares of Crinetics Pha - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Stephanie Okey Sells 3,000 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CFO Tobin Schilke Sells 6,713 Shares - MarketBeat
CRNX: Strong launch, advancing pipeline, and EU expansion position for major growth in rare endocrine diseases - TradingView
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Analysis: Unpacking a 105% Potential Upside for Growth Investors - DirectorsTalk Interviews
Why Crinetics Pharmaceuticals (CRNX) Is Down 7.1% After Deeper 2025 Loss And New US$207 Million Shelf Registration - Sahm
Does Crinetics Pharmaceuticals, Inc. (CRNX) Have Momentum? - AAII.com
CRNX: Analyst Maintains "Market Outperform" but Lowers Price Tar - GuruFocus
Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00 - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
(CRNX) Risk Channels and Responsive Allocation - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Crinetics Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CRNX) 2026-02-27 - Seeking Alpha
Crinetics Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vanguard Group Inc. Sells 86,003 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Palsonfi Launch Momentum And ESOP Shelf Registration Altering The Investment Case For Crinetics (CRNX)? - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Q4 2025 Earnings Call Highl - GuruFocus
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals (CRNX) Reports Strong Q4 2025 Performa - GuruFocus
Crinetics Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Crinetics Pharmaceuticals Q4 2025 earnings beat forecasts - Investing.com
Crinetics (CRNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Crinetics Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Crinetics (CRNX) Exceeds Revenue Expectations and Looks to Expan - GuruFocus
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Crinetics Pharmaceuticals Q4 Loss Widens - marketscreener.com
Earnings Flash (CRNX) Crinetics Pharmaceuticals Posts Q4 Loss $1.29, vs. FactSet Est of $1.35 Loss - marketscreener.com
Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q4 Revenue $6.2M, vs. FactSet Est of $4.5M - marketscreener.com
Crinetics Pharmaceuticals Reports $5.4 Million in Q4 2025 Net Revenue from PALSONIFY™ and Plans for Phase 2/3 Study of Atumelnant in 2026 - Quiver Quantitative
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Crinetics earnings on deck: Can drug launch offset mounting losses? - Investing.com Australia
Crinetics earnings on deck: Can drug launch offset mounting losses? By Investing.com - Investing.com South Africa
JPMorgan Chase & Co. Grows Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
US Market Recap: Should value investors consider Crinetics Pharmaceuticals Inc2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Preview: Crinetics Pharmaceuticals's Earnings - Benzinga
Crinetics (CRNX) COO Jeff Knight granted 55,000 options and 34,000 RSUs - Stock Titan
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: A Potential 94% Upside Lures Investors - DirectorsTalk Interviews
Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback - Yahoo Finance
Crinetics Progresses Rare Endocrine Pipeline With New Data And Early Sales - simplywall.st
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - StreetInsider
NEOS Investment Management LLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by Skandinaviska Enskilda Banken AB publ - MarketBeat
Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Market Recap: What is the next catalyst for BTCTJuly 2025 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday - MarketBeat
Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug - Insider Monkey
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):